Immunostaining for the HCC biomarkers AFP and GP73 and the ICC biomarker CK19 revealed the presence of HCC, ICC, and mixed HCC-ICC types in mouse liver tumors induced by CRISPR/Cas9 (Fig. 1D). This evidence concerns the gene GOLM1 and intrahepatic cholangiocarcinoma.